Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $341.6K | $1.5M | $5.8M | $3.0M | $2.9M | $2.1M |
| Cost of revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Gross profit | $0 | $0 | $341.6K | $1.5M | $5.8M | $3.0M | $2.9M | $2.1M |
| Gross margin | — | — | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% |
| R&D | $2.9M | $2.6M | $9.3M | $8.3M | $16.2M | $13.0M | $12.9M | $18.8M |
| Operating income | −$12.2M | −$21.0M | −$13.1M | −$13.3M | −$18.0M | −$20.7M | −$26.1M | −$35.4M |
| EBITDA | −$11.6M | −$19.8M | −$11.9M | −$12.5M | −$16.5M | −$19.7M | −$25.7M | −$35.4M |
| Net income | −$11.8M | −$20.3M | −$12.6M | −$11.8M | −$15.7M | −$20.0M | −$26.0M | −$35.4M |
| Net margin | — | — | -3680.4% | -779.1% | -271.6% | -656.5% | -883.7% | -1675.5% |
| EPS (diluted) | -126.18 | -174.92 | -49.40 | -21.56 | -6.30 | -4.21 | -1.63 | -1.41 |
Annual figures · source: Financial Modeling Prep
No one on the platform currently holds HTBX.
No tracked institution reports a position in HTBX as of their last filing.
| Execution date | Ratio |
|---|---|
| 2020-12-11 | 1-for-7reverse |
| 2018-01-22 | 1-for-10reverse |
No one on the platform has traded HTBX yet.
| $54M |
| — |
| QNCXQuince Therapeutics, Inc. | $0.92 | -2.43% | $5M | — |
| RPHMReneo Pharmaceuticals, Inc. | $18.20 | +952.02% | $61M | — |
Source: Financial Modeling Prep · peers by sector/industry
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.